Phase Ib/II trial of pembrolizumab (pembro) plus lenvatinib combination therapy in patients (pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts E and F

被引：0
|
作者：
Kramer, G. [1 ]
Shore, N. D. [2 ]
Joshua, A. M. [3 ]
Li, X. T. [4 ]
Poehlein, C. H. [4 ]
Schloss, C. [4 ]
de Bono, J. S. [5 ]
Yu, E. [6 ]
机构：
[1] Med Univ Vienna, Urol, Vienna, Austria
[2] Carolina Urol Res Ctr, Urol, Myrtle Beach, SC USA
[3] St Vincents Hosp Sydney, Med Oncol, Sydney, NSW, Australia
[4] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[5] Royal Marsden NHS Fdn Trust, Med Oncol, London, England
[6] Univ Washington, Med Oncol, Seattle, WA 98195 USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1153
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
640TiP
引用
收藏
页码：S669 / S670
页数：2
相关论文
共 50 条
  • [41] KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Kolinsky, Michael Paul
    Gravis, Gwenaelle
    Mourey, Loic
    Piulats, Josep M.
    Sridhar, Srikala S.
    Romano, Emanuela
    Berry, William R.
    Gurney, Howard
    Retz, Margitta
    Appleman, Leonard Joseph
    Boegemann, Martin
    De Bono, Johann S.
    Joshua, Anthony M.
    Emmenegger, Urban
    Conter, Henry Jacob
    Laguerre, Brigitte
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [42] PHASE 3 TRIAL OF PEMBROLIZUMAB AND ENZALUTAMIDE VERSUS ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) (KEYNOTE-641)
    Graff, Julie Nicole
    Burgents, Joseph
    Liang, Li Wen
    Stenzl, Arnulf
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A210 - A210
  • [43] Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.
    Fong, Peter C. C.
    Retz, Margitta
    Drakaki, Alexandra
    Massard, Christophe
    Berry, William R.
    Romano, Emanuela
    De Bono, Johann S.
    Feyerabend, Susan
    Appleman, Leonard Joseph
    Conter, Henry Jacob
    Sridhar, Srikala S.
    Shore, Neal D.
    Linch, Mark David
    Joshua, Anthony M.
    Gurney, Howard
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone acetate (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-921
    Petrylak, Daniel Peter
    Shore, Neal D.
    Bennamoun, Mostefa
    Ratta, Raffaele
    Piulats, Josep M.
    Li, Ben
    Schloss, Charles
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [45] Phase Ib study of niraparib plus androgen receptor-targeted therapy (ART) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Saad, Fred
    Chi, Kim N.
    Shore, Neal D.
    Graff, Julie Nicole
    Posadas, Edwin M.
    Espina, Byron M.
    Zhu, Eugene
    Hazra, Anasuya
    Bradic, Branislav
    Cheng, Shinta
    Hayreh, Vinny
    Rezazadeh, Arash
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [46] Biomarker analysis from the KEYNOTE-199 trial of pembrolizumab in patients (pts) with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
    Antonarakis, Emmanuel S.
    Rodriguez, Jose Maria M. Piulats
    Gross-Goupil, Marine
    Goh, Jeffrey C.
    Vaishampayan, Ulka N.
    De Wit, Ronald
    Alanko, Tuomo
    Fukasawa, Satoshi
    Tabata, Kenichi
    Feyerabend, Susan
    Berger, Raanan
    Wu, Haiyan
    Kim, Jeri
    Schloss, Charles
    Qiu, Ping
    Suttner, Leah
    Cristescu, Razvan
    Marton, Matthew John
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update
    Omlin, A. G.
    Graff, J. N.
    Hoimes, C. J.
    Tagawa, S. T.
    Hwang, C.
    Kilari, D.
    Ten Tije, A. J.
    McDermott, R.
    Vaishampayan, U. N.
    Elliott, T.
    Gerritsen, W. R.
    Wu, H.
    Kim, J.
    Schloss, C.
    de Bono, J. S.
    Antonarakis, E. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S514 - S515
  • [48] Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.
    Yu, Evan Y.
    Joshua, Anthony M.
    Shore, Neal D.
    Kramer, Gero
    Hu, Haixia
    Poehlein, Christian Heinrich
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS250 - TPS250
  • [49] Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.
    Clarke, Noel
    Wiechno, Pawel J.
    Alekseev, Boris
    Sala, Nuria
    Jones, Robert
    Kocak, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Phase I trial with a combination of docetaxel and 153Sm- EDTMP in patients (pts) with castration-resistant metastatic prostate cancer (mCRPC)
    Eisenberger, M. A.
    Lin, J.
    Sinibaldi, V. J.
    Carducci, M. A.
    Denmeade, S.
    DeWeese, T.
    Song, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345